Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease

<p>Abstract</p> <p>Purpose</p> <p>We hypothesized that quantitative PET parameters may have predictive value beyond that of traditional clinical factors such as the International Prognostic Score (IPS) among Hodgkin's disease (HD) patients.</p> <p>Metho...

Full description

Bibliographic Details
Main Authors: Tseng Diane, Rachakonda Leelanand P, Su Zheng, Advani Ranjana, Horning Sandra, Hoppe Richard T, Quon Andrew, Graves Edward E, Loo Billy W, Tran Phuoc T
Format: Article
Language:English
Published: BMC 2012-01-01
Series:Radiation Oncology
Subjects:
PET
Online Access:http://www.ro-journal.com/content/7/1/5
id doaj-e53941013b4746098a03793a6ef1a1de
record_format Article
spelling doaj-e53941013b4746098a03793a6ef1a1de2020-11-24T21:13:35ZengBMCRadiation Oncology1748-717X2012-01-0171510.1186/1748-717X-7-5Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's diseaseTseng DianeRachakonda Leelanand PSu ZhengAdvani RanjanaHorning SandraHoppe Richard TQuon AndrewGraves Edward ELoo Billy WTran Phuoc T<p>Abstract</p> <p>Purpose</p> <p>We hypothesized that quantitative PET parameters may have predictive value beyond that of traditional clinical factors such as the International Prognostic Score (IPS) among Hodgkin's disease (HD) patients.</p> <p>Methods</p> <p>Thirty HD patients treated at presentation or relapse had staging and interim-treatment PET-CT scans. The majority of patients (53%) had stage III-IV disease and 67% had IPS ≥ 2. Interim-treatment scans were performed at a median of 55 days from the staging PET-CT. Chemotherapy regimens used: Stanford V (67%), ABVD (17%), VAMP (10%), or BEACOPP (7%). Hypermetabolic tumor regions were segmented semiautomatically and the metabolic tumor volume (MTV), mean standardized uptake value (SUVmean), maximum SUV (SUVmax) and integrated SUV (iSUV) were recorded. We analyzed whether IPS, absolute value PET parameters or the calculated ratio of interim- to pre-treatment PET parameters were associated with progression free survival (PFS) or overall survival (OS).</p> <p>Results</p> <p>Median follow-up of the study group was 50 months. Six of the 30 patients progressed clinically. Absolute value PET parameters from pre-treatment scans were not significant. Absolute value SUVmax from interim-treatment scans was associated with OS as determined by univariate analysis (p < 0.01). All four calculated PET parameters (interim/pre-treatment values) were associated with OS: MTV<sub>int/pre </sub>(<it>p </it>< 0.01), SUVmean<sub>int/pre </sub>(<it>p </it>< 0.05), SUVmax<sub>int/pre </sub>(<it>p </it>= 0.01), and iSUV<sub>int/pre </sub>(<it>p </it>< 0.01). Absolute value SUVmax from interim-treatment scans was associated with PFS (p = 0.01). Three calculated PET parameters (int/pre-treatment values) were associated with PFS: MTV<sub>int/pre </sub>(<it>p </it>= 0.01), SUVmax<sub>int/pre </sub>(<it>p </it>= 0.02) and iSUV<sub>int/pre </sub>(<it>p </it>= 0.01). IPS was associated with PFS (<it>p </it>< 0.05) and OS (<it>p </it>< 0.01).</p> <p>Conclusions</p> <p>Calculated PET metrics may provide predictive information beyond that of traditional clinical factors and may identify patients at high risk of treatment failure early for treatment intensification.</p> http://www.ro-journal.com/content/7/1/5Hodgkin's diseasePETmetabolic tumor volumequantitative PET parameterssurvival
collection DOAJ
language English
format Article
sources DOAJ
author Tseng Diane
Rachakonda Leelanand P
Su Zheng
Advani Ranjana
Horning Sandra
Hoppe Richard T
Quon Andrew
Graves Edward E
Loo Billy W
Tran Phuoc T
spellingShingle Tseng Diane
Rachakonda Leelanand P
Su Zheng
Advani Ranjana
Horning Sandra
Hoppe Richard T
Quon Andrew
Graves Edward E
Loo Billy W
Tran Phuoc T
Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
Radiation Oncology
Hodgkin's disease
PET
metabolic tumor volume
quantitative PET parameters
survival
author_facet Tseng Diane
Rachakonda Leelanand P
Su Zheng
Advani Ranjana
Horning Sandra
Hoppe Richard T
Quon Andrew
Graves Edward E
Loo Billy W
Tran Phuoc T
author_sort Tseng Diane
title Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
title_short Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
title_full Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
title_fullStr Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
title_full_unstemmed Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
title_sort interim-treatment quantitative pet parameters predict progression and death among patients with hodgkin's disease
publisher BMC
series Radiation Oncology
issn 1748-717X
publishDate 2012-01-01
description <p>Abstract</p> <p>Purpose</p> <p>We hypothesized that quantitative PET parameters may have predictive value beyond that of traditional clinical factors such as the International Prognostic Score (IPS) among Hodgkin's disease (HD) patients.</p> <p>Methods</p> <p>Thirty HD patients treated at presentation or relapse had staging and interim-treatment PET-CT scans. The majority of patients (53%) had stage III-IV disease and 67% had IPS ≥ 2. Interim-treatment scans were performed at a median of 55 days from the staging PET-CT. Chemotherapy regimens used: Stanford V (67%), ABVD (17%), VAMP (10%), or BEACOPP (7%). Hypermetabolic tumor regions were segmented semiautomatically and the metabolic tumor volume (MTV), mean standardized uptake value (SUVmean), maximum SUV (SUVmax) and integrated SUV (iSUV) were recorded. We analyzed whether IPS, absolute value PET parameters or the calculated ratio of interim- to pre-treatment PET parameters were associated with progression free survival (PFS) or overall survival (OS).</p> <p>Results</p> <p>Median follow-up of the study group was 50 months. Six of the 30 patients progressed clinically. Absolute value PET parameters from pre-treatment scans were not significant. Absolute value SUVmax from interim-treatment scans was associated with OS as determined by univariate analysis (p < 0.01). All four calculated PET parameters (interim/pre-treatment values) were associated with OS: MTV<sub>int/pre </sub>(<it>p </it>< 0.01), SUVmean<sub>int/pre </sub>(<it>p </it>< 0.05), SUVmax<sub>int/pre </sub>(<it>p </it>= 0.01), and iSUV<sub>int/pre </sub>(<it>p </it>< 0.01). Absolute value SUVmax from interim-treatment scans was associated with PFS (p = 0.01). Three calculated PET parameters (int/pre-treatment values) were associated with PFS: MTV<sub>int/pre </sub>(<it>p </it>= 0.01), SUVmax<sub>int/pre </sub>(<it>p </it>= 0.02) and iSUV<sub>int/pre </sub>(<it>p </it>= 0.01). IPS was associated with PFS (<it>p </it>< 0.05) and OS (<it>p </it>< 0.01).</p> <p>Conclusions</p> <p>Calculated PET metrics may provide predictive information beyond that of traditional clinical factors and may identify patients at high risk of treatment failure early for treatment intensification.</p>
topic Hodgkin's disease
PET
metabolic tumor volume
quantitative PET parameters
survival
url http://www.ro-journal.com/content/7/1/5
work_keys_str_mv AT tsengdiane interimtreatmentquantitativepetparameterspredictprogressionanddeathamongpatientswithhodgkinsdisease
AT rachakondaleelanandp interimtreatmentquantitativepetparameterspredictprogressionanddeathamongpatientswithhodgkinsdisease
AT suzheng interimtreatmentquantitativepetparameterspredictprogressionanddeathamongpatientswithhodgkinsdisease
AT advaniranjana interimtreatmentquantitativepetparameterspredictprogressionanddeathamongpatientswithhodgkinsdisease
AT horningsandra interimtreatmentquantitativepetparameterspredictprogressionanddeathamongpatientswithhodgkinsdisease
AT hopperichardt interimtreatmentquantitativepetparameterspredictprogressionanddeathamongpatientswithhodgkinsdisease
AT quonandrew interimtreatmentquantitativepetparameterspredictprogressionanddeathamongpatientswithhodgkinsdisease
AT gravesedwarde interimtreatmentquantitativepetparameterspredictprogressionanddeathamongpatientswithhodgkinsdisease
AT loobillyw interimtreatmentquantitativepetparameterspredictprogressionanddeathamongpatientswithhodgkinsdisease
AT tranphuoct interimtreatmentquantitativepetparameterspredictprogressionanddeathamongpatientswithhodgkinsdisease
_version_ 1716748763355152384